These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 19853357

  • 1. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
    Kalogeromitros D, Makris M, Koti I, Chliva C, Mellios A, Avgerinou G, Theoharides TC.
    Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
    [Abstract] [Full Text] [Related]

  • 2. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G, Sin BA, Misirligil Z.
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [Abstract] [Full Text] [Related]

  • 3. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A, Yogev A, Confino-Cohen R.
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [Abstract] [Full Text] [Related]

  • 4. Basophil sensitivity in patients not responding to venom immunotherapy.
    Peternelj A, Silar M, Erzen R, Kosnik M, Korosec P.
    Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
    [Abstract] [Full Text] [Related]

  • 5. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
    Oren E, Chegini S, Hamilos DL.
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):606-10. PubMed ID: 17165267
    [Abstract] [Full Text] [Related]

  • 6. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
    Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, Lombardo C, Roncallo C, Patriarca G.
    Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
    [Abstract] [Full Text] [Related]

  • 7. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L, Chelminska M, Kuziemski K, Skrzypski M, Niedoszytko M, Damps-Konstanska I, Szymanowska A, Siemińska A, Wajda B, Drozdowska A, Jutel M, Jassem E.
    Int Arch Allergy Immunol; 2008 Apr; 147(3):241-5. PubMed ID: 18594155
    [Abstract] [Full Text] [Related]

  • 8. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC, Pedro E, Spínola Santos A, Branco Ferreira M, Palma Carlos ML, Palma Carlos AG.
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [Abstract] [Full Text] [Related]

  • 9. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
    Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Kucharewicz I, Küchenhoff H, Lang R, Quercia O, Reider N, Severino M, Sticherling M, Sturm GJ, Wüthrich B, European Academy of Allergy and Clinical Immunology Interest Group.
    J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
    [Abstract] [Full Text] [Related]

  • 10. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
    Díez Gómez ML, Quirce Gancedo S, Juliá de Páramo B.
    Allergol Immunopathol (Madr); 1995 Jul; 23(6):277-84. PubMed ID: 8579006
    [Abstract] [Full Text] [Related]

  • 11. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F, Wenderoth A, Przybilla B.
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [Abstract] [Full Text] [Related]

  • 12. [The estimation of treatment of Hymenoptera venoms allergy in children].
    Botulińska E, Piotrowska T, Korol D, Swiebocka E, Hofman J.
    Pol Merkur Lekarski; 2006 Sep; 21(123):232-4. PubMed ID: 17163183
    [Abstract] [Full Text] [Related]

  • 13. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
    Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL.
    Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
    [Abstract] [Full Text] [Related]

  • 14. Systemic and local reactions of bee venom immunotherapy in Iran.
    Bemanian MH, Farhoudi A, Pourpak Z, Gharagozlou M, Movahedi M, Nabavi M, Mozafari H, Mohammadzadeh I, Chavoshzadeh Z, Shirkhoda Z.
    Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
    [Abstract] [Full Text] [Related]

  • 15. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy.
    White KM, England RW.
    Ann Allergy Asthma Immunol; 2008 Oct; 101(4):426-30. PubMed ID: 18939733
    [Abstract] [Full Text] [Related]

  • 16. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
    Verburg M, Oldhoff JM, Klemans RJ, Lahey-de Boer A, de Bruin-Weller MS, Röckmann H, Sanders C, Bruijnzeel-Koomen CA, Pasmans SG, Knulst AC.
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
    [Abstract] [Full Text] [Related]

  • 17. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
    Goldberg A, Confino-Cohen R.
    Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
    [Abstract] [Full Text] [Related]

  • 18. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
    González de Olano D, Alvarez-Twose I, Esteban-López MI, Sánchez-Muñoz L, de Durana MD, Vega A, García-Montero A, González-Mancebo E, Belver T, Herrero-Gil MD, Fernández-Rivas M, Orfao A, de la Hoz B, Castells MC, Escribano L.
    J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
    [Abstract] [Full Text] [Related]

  • 19. Hymenoptera venom immunotherapy and field stings.
    Lang R, Hawranek T.
    J Investig Allergol Clin Immunol; 2006 Feb; 16(4):224-31. PubMed ID: 16889279
    [Abstract] [Full Text] [Related]

  • 20. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
    Pereira-Santos MC, Baptista AP, Melo A, Alves RR, Soares RS, Pedro E, Pereira-Barbosa M, Victorino RM, Sousa AE.
    Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.